Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Goldman Sachs upgrades Dr Martens to 'buy'

Tue 13 July 2021 09:43 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Goldman Sachs upped Dr Martens to 'buy' from 'neutral' on Tuesday, hiking the price target to 535p from 490p.

In a note back in March, the bank had already highlighted three drivers underpinning the company's growth profile: global expansion, eg in the US and China; enhanced brand control by bringing third party distributor markets in house; expanding DTC sales.

The bank said that it has taken a deeper look at the potential in converting distributor markets, with a particular focus on Italy.

"Using the success that Dr Martens has seen converting Germany two years ago as a reference point, we forecast Italy can achieve forecast Italy can achieve circa £65m of sales by FY23E (versus c£20m in FY21, on our estimates).

"We now forecast that Dr Martens can grow revenue by 23%/18%/16% in FY22/23/24E (versus 19%/16%/15% prior)."

At 1045 BST, the shares were up 2.2% at 456p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.